Markets

Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% - Tale of the Tape

Lexicon Pharmaceuticals, Inc. ( LXRX ) was a big mover last session, as its shares rose over 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the company since Sep 24, as the stock is now down over 10%.

In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Lexicon Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other better-ranked biomedical stocks include Halozyme Therapeutics, Inc. ( HALO ), Merrimack Pharmaceuticals, Inc. ( MACK ) and Myriad Genetics Inc. ( MYGN ). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LEXICON PHARMA (LXRX): Free Stock Analysis Report

MYRIAD GENETICS (MYGN): Free Stock Analysis Report

MERRIMACK PHAR (MACK): Free Stock Analysis Report

HALOZYME THERA (HALO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MACK HALO LXRX MYGN

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More